Menu
Advanced
Structure search
List search
EN
CN
ES
FR
JP
KR
Wish Lists
Cart
Sign in
Sign in
Contact us
Catalog
of Screening Compounds
Screening Libraries
Building Blocks
Al/ML Data sets
new
Advanced
Structure search
List search
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
Merck's antiviral drug meets main goal in late-stage trial
Merck & Co Inc said its experimental drug to prevent cytomegalovirus infection in high-risk bone marrow transplant patients met its primary goal in a late-stage trial.
Canadian Ebola vaccine enters new trial phase
OTTAWA, Canada I October 18, 2016 I Today, the Honourable Marie-Claude Bibeau, Minister of International Development and La Francophonie, together with the Honourable Jane Philpott, Minister of Health...
ADC Therapeutics Announces Closing of $105 Million Private Financing
LAUSANNE, Switzerland I October 18, 2016 I ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugat...
Colombian pharmaceutical market to see strong market growth, surpassing $7 billion by 2020, says GlobalData
The pharmaceutical market in Colombia is set to rise from $5 billion in 2015 to $7.
New molecule may help fight obesity
Researchers, including one of Indian-origin, have identified a new molecule that may help fight obesity and other metabolic diseases by converting 'bad' fat to 'good' fat.
Teva Receives Positive Opinion from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to Extend Indication of Trisenox® for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia (APL)
JERUSALEM, Israel I October 17, 2016 I Teva Pharmaceutical Industries Ltd.
Unvaccinated adults cost the US more than $7 billion a year
Vaccine-preventable diseases among adults cost the U.
Major depressive disorder market will reach $5.8 billion by 2025 as awareness and drugs improve, says GlobalData
The major depressive disorder (MDD) market, which covers various forms of depression and seasonal affective disorder, is set to rise from $3.
PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop
BERNARDSVILLE, NJ, USA I October 14, 2016 I PanOptica, Inc.
Trevi Therapeutics Announces Positive Results from Phase 2 Trial in Prurigo Nodularis
NEW HAVEN, CT, USA I October 13, 2016 I Trevi Therapeutics, Inc.
Generic drugs “save European 100 billion euros per year”
Through generic medicine competition, twice as many patients were able to get treatment without any impact on the treatment cost, according to the conclusions of the IMS Institute for Healthcare Infor...
Major depressive disorder market will reach $5.8 billion by 2025 as awareness and drugs improve, says GlobalData
The major depressive disorder (MDD) market, which covers various forms of depression and seasonal affective disorder, is set to rise from $3.
8
9
10
11
12
13
14
15
16
0
item
s
in Cart
Cart Subtotal:
Go to cart
You will be able to Pay Online or Request a Quote
Catalog
Services
Company
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Preplated libraries
Inhibitors and Approved Drugs
Screening Compounds
Building blocks
Inhibitors and approved drugs
Drug Discovery Services
Al/ML Data sets
Synthetic and Medicinal Chemistry
In silico drug design (CADD)
Discovery biology
ADME, DMPK
Functional ex vivo and in vivo models
Safety and Toxicology
Company
News & Media
Contact us
Trends in discovery compounds
